IONS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 672.98 -- higher than 94.39% of US-listed equities with positive expected earnings growth.
The price/operating cash flow metric for Ionis Pharmaceuticals Inc is higher than 89.38% of stocks in our set with a positive cash flow.
The volatility of Ionis Pharmaceuticals Inc's share price is greater than that of just 5.18% US stocks with at least 200 days of trading history.
Stocks that are quantitatively similar to IONS, based on their financial statements, market capitalization, and price volatility, are ACRS, SWKS, RESN, TBPH, and ACIA.
Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
IONS Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Ionis Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Ionis Pharmaceuticals Inc ranked in the 31th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 50%. As for the metrics that stood out in our discounted cash flow analysis of Ionis Pharmaceuticals Inc, consider:
The company has produced more trailing twelve month cash flow than 56.72% of its sector Healthcare.
91% of the company's capital comes from equity, which is greater than 78.42% of stocks in our cash flow based forecasting set.
The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 21.54% of the free cash flow producing stocks we're observing.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Ionis Pharmaceuticals Inc? See PDEX, ZTS, ESMC, PRAH, and XRAY.
Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2020 financial results and report on pipeline and business progress.
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Christophe Hotermans, M.D., Ph.D., has joined the company as senior vice president of global medical affairs where he will lead and evolve the execution of medical strategies, activities and operations worldwide in collaboration with executive management.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]